Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples